HK1213495A1 - 用於治療和診斷急性心肌梗死的方法和組合物 - Google Patents

用於治療和診斷急性心肌梗死的方法和組合物

Info

Publication number
HK1213495A1
HK1213495A1 HK16101638.8A HK16101638A HK1213495A1 HK 1213495 A1 HK1213495 A1 HK 1213495A1 HK 16101638 A HK16101638 A HK 16101638A HK 1213495 A1 HK1213495 A1 HK 1213495A1
Authority
HK
Hong Kong
Prior art keywords
compositions
treating
methods
myocardial infarction
acute myocardial
Prior art date
Application number
HK16101638.8A
Other languages
English (en)
Inventor
Slobodan Vukicevic
Lovorka Grgurevic
Ivo Dumic-Cule
Original Assignee
Genera Istrazivanja D O O
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genera Istrazivanja D O O filed Critical Genera Istrazivanja D O O
Publication of HK1213495A1 publication Critical patent/HK1213495A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
HK16101638.8A 2012-04-25 2016-02-16 用於治療和診斷急性心肌梗死的方法和組合物 HK1213495A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261638373P 2012-04-25 2012-04-25
US201261638424P 2012-04-25 2012-04-25
PCT/US2013/038294 WO2013163479A1 (en) 2012-04-25 2013-04-25 Methods and compositions for treating and diagnosing acute myocardial infarction

Publications (1)

Publication Number Publication Date
HK1213495A1 true HK1213495A1 (zh) 2016-07-08

Family

ID=49483906

Family Applications (2)

Application Number Title Priority Date Filing Date
HK15102292.4A HK1201732A1 (zh) 2012-04-25 2015-03-06 治療與診斷急性心肌梗死的方法與組合物
HK16101638.8A HK1213495A1 (zh) 2012-04-25 2016-02-16 用於治療和診斷急性心肌梗死的方法和組合物

Family Applications Before (1)

Application Number Title Priority Date Filing Date
HK15102292.4A HK1201732A1 (zh) 2012-04-25 2015-03-06 治療與診斷急性心肌梗死的方法與組合物

Country Status (9)

Country Link
US (1) US20150104455A1 (zh)
EP (1) EP2841100A4 (zh)
JP (1) JP6133402B2 (zh)
CN (1) CN104853773A (zh)
AU (1) AU2013251442B2 (zh)
CA (1) CA2870365A1 (zh)
HK (2) HK1201732A1 (zh)
NZ (1) NZ631639A (zh)
WO (1) WO2013163479A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2936467A1 (en) 2014-01-10 2015-07-16 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use
WO2017006295A1 (en) 2015-07-08 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited Hydroxy formamide derivatives and their use
WO2017006296A1 (en) 2015-07-09 2017-01-12 Glaxosmithkline Intellectual Property (No.2) Limited N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors
BR112023001646A2 (pt) 2020-07-31 2023-04-04 Glaxosmithkline Ip Dev Ltd Proteínas de ligação a bmp1, tll1 e/ou tll2, método para a produção das mesmas, sequência polinucleotídica, vetor de expressão, célula hospedeira recombinante, composição farmacêutica e usos das ditas proteínas ou composição para tratar uma doença ou distúrbio relacionado à fibrose e promover o crescimento muscular e/ou melhorar a função muscular
CN117074698B (zh) * 2023-10-11 2024-03-15 湖南凯莱谱生物科技有限公司 用于急性心肌梗死早期诊断的标志物组合、试剂盒、系统和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6037139A (en) * 1997-06-03 2000-03-14 Wisconsin Alumni Research Foundation System for assaying modulators of procollagen maturation
US20030224501A1 (en) * 2000-03-17 2003-12-04 Young Paul E. Bone morphogenic protein polynucleotides, polypeptides, and antibodies
AU2003295328A1 (en) * 2002-10-02 2004-04-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2008011193A2 (en) * 2006-07-21 2008-01-24 Genera Doo Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders
US8703435B2 (en) * 2007-04-20 2014-04-22 University Of Louisville Research Foundation, Inc. Peptide biomarkers of cardiovascular disease
SI2254586T1 (sl) * 2008-02-22 2015-07-31 Agency For Science, Technology And Research (A*Star) Delci mezenhimske matične celice
TWI492707B (zh) * 2009-05-20 2015-07-21 卡迪歐參生物科技有限公司 治療心臟疾病之藥品配方

Also Published As

Publication number Publication date
EP2841100A4 (en) 2016-03-23
CN104853773A (zh) 2015-08-19
JP6133402B2 (ja) 2017-05-24
NZ631639A (en) 2016-09-30
EP2841100A1 (en) 2015-03-04
WO2013163479A1 (en) 2013-10-31
JP2015520736A (ja) 2015-07-23
HK1201732A1 (zh) 2015-09-11
AU2013251442B2 (en) 2017-07-06
US20150104455A1 (en) 2015-04-16
CA2870365A1 (en) 2013-10-31
AU2013251442A1 (en) 2014-10-02

Similar Documents

Publication Publication Date Title
HK1214521A1 (zh) 用於治療蛋白質病的組合物和方法
ZA201408580B (en) Detergent composition
EP2922861A4 (en) BIOMARKER COMPOSITIONS AND METHODS
EP2823306A4 (en) BIOMARKER COMPOSITIONS AND METHODS
HK1251796A1 (zh) 治療糖尿病的方法和組合物
EP2875826A4 (en) COMPOSITION FOR PREVENTING OR TREATING SEPSIS
PL2662436T3 (pl) Kompozycja detergentu
HK1207109A1 (zh) 用於治療澱粉狀蛋白沉積的方法和組合物
HK1209633A1 (zh) 治療糖尿病的組合物和方法
EP2834638A4 (en) METHODS AND COMPOSITIONS FOR DIAGNOSIS AND PROGNOSIS OF A SEPSIS
GB201200707D0 (en) Composition
EP2897630A4 (en) ANTI-INFLAMMATORY COMPOSITIONS FOR THE TREATMENT OF NEUROGENIC INFLAMMATION
HK1213495A1 (zh) 用於治療和診斷急性心肌梗死的方法和組合物
EP2878295A4 (en) COMPOSITION
EP2931280A4 (en) METHOD AND COMPOSITIONS FOR INHIBITING CNKSR1
EP2726109A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKELETAL MYOPATHY
GB201206035D0 (en) Composition
EP2875347A4 (en) METHODS AND COMPOSITIONS FOR THE DIAGNOSIS AND PROGNOSIS OF SEPSIS
EP2837670A4 (en) COMPOSITION CONTAINING FLUOROBIPHENYL
ZA201500291B (en) Bright detergent composition
EP2910538A4 (en) AGENT COMPOSITION GENERATING GAS
EP2910537A4 (en) AGENT COMPOSITION GENERATING GAS
GB201209597D0 (en) Composition
GB201208133D0 (en) Composition
IL239426A0 (en) Methods and compositions of biomarkers